The answer is A, crovalimab (PiaSky), a complement C5 inhibitor, treats paroxysmal nocturnal hemoglobinuria. The rest: Imetelstat (Rytelo), an oligonucleotide telomerase inhibitor, treats patients with myelodysplastic syndromes with transfusion-dependent anemia;
More
2/3
More
2/3
December 26, 2024 at 6:52 PM
The answer is A, crovalimab (PiaSky), a complement C5 inhibitor, treats paroxysmal nocturnal hemoglobinuria. The rest: Imetelstat (Rytelo), an oligonucleotide telomerase inhibitor, treats patients with myelodysplastic syndromes with transfusion-dependent anemia;
More
2/3
More
2/3
Checking out PiaSky® label and I see this: "Injection: 340 mg/2 mL (170 mg/mL) as a clear to opalescent and almost colorless to brownish-yellow solution in a single-dose vial." Hey CMC, clear to brownish-yellow? That inspires confidence in the purification methodology.
August 31, 2026 at 3:43 PM
Checking out PiaSky® label and I see this: "Injection: 340 mg/2 mL (170 mg/mL) as a clear to opalescent and almost colorless to brownish-yellow solution in a single-dose vial." Hey CMC, clear to brownish-yellow? That inspires confidence in the purification methodology.
A year of searching—and this one was worth the wait. 🏡
Our first-time buyers found their new home in Eagle Rock, one of the neighborhoods at the top of their list, and we closed in just 27 days.
Congratulations to our buyers, and thanks to listing agent Terry Piasky of Coldwell Banker Realty.
Our first-time buyers found their new home in Eagle Rock, one of the neighborhoods at the top of their list, and we closed in just 27 days.
Congratulations to our buyers, and thanks to listing agent Terry Piasky of Coldwell Banker Realty.
August 25, 2026 at 4:21 PM
A year of searching—and this one was worth the wait. 🏡
Our first-time buyers found their new home in Eagle Rock, one of the neighborhoods at the top of their list, and we closed in just 27 days.
Congratulations to our buyers, and thanks to listing agent Terry Piasky of Coldwell Banker Realty.
Our first-time buyers found their new home in Eagle Rock, one of the neighborhoods at the top of their list, and we closed in just 27 days.
Congratulations to our buyers, and thanks to listing agent Terry Piasky of Coldwell Banker Realty.
Piasky (Crovalimab) | Relatório de avaliação de financiamento público disponível na Infomed | Deferimento do pedido de avaliação prévia
swki.me/KmSRY9Oz
#infarmed #medicamentos #financiamentopublico #piasky #crovalimab
swki.me/KmSRY9Oz
#infarmed #medicamentos #financiamentopublico #piasky #crovalimab
August 24, 2026 at 2:28 PM
Piasky (Crovalimab) | Relatório de avaliação de financiamento público disponível na Infomed | Deferimento do pedido de avaliação prévia
swki.me/KmSRY9Oz
#infarmed #medicamentos #financiamentopublico #piasky #crovalimab
swki.me/KmSRY9Oz
#infarmed #medicamentos #financiamentopublico #piasky #crovalimab
#SMCapproval #Haematology #crovalimab #Piasky #Roche #NHSScotland #paroxysmalnocturnalhaemoglobinuria #PNH #orphanequivalentprocess #humanisedanticomplementcomponentC5antibody #SequentialMonoclonalAntibodyRecyclingTechnology #COMMODORE2clinicalstudy
scottishmedicines.org.uk/medicines-ad...
scottishmedicines.org.uk/medicines-ad...
January 22, 2025 at 12:05 PM
More year-end review. Which novel drug of 2024 treats paroxysmal nocturnal hemoglobinuria?
A. Crovalimab (PiaSky)
B. Imetelstat (Rytelo)
C. Pneumococcal 21-valent conjugate vaccine (Capvaxive)
D. Sofpironium (Sofdra)
The answer is in the thread
1/3
#PhunQuiz
A. Crovalimab (PiaSky)
B. Imetelstat (Rytelo)
C. Pneumococcal 21-valent conjugate vaccine (Capvaxive)
D. Sofpironium (Sofdra)
The answer is in the thread
1/3
#PhunQuiz
December 26, 2024 at 6:52 PM
More year-end review. Which novel drug of 2024 treats paroxysmal nocturnal hemoglobinuria?
A. Crovalimab (PiaSky)
B. Imetelstat (Rytelo)
C. Pneumococcal 21-valent conjugate vaccine (Capvaxive)
D. Sofpironium (Sofdra)
The answer is in the thread
1/3
#PhunQuiz
A. Crovalimab (PiaSky)
B. Imetelstat (Rytelo)
C. Pneumococcal 21-valent conjugate vaccine (Capvaxive)
D. Sofpironium (Sofdra)
The answer is in the thread
1/3
#PhunQuiz
La AEMPS emite nuevos IPT para cinco medicamentos oncológicos, entre ellos Tevimbra y Opdivo elglobalfarma.com/politica/aem...
La AEMPS emite nuevos IPT para cinco medicamentos oncológicos, entre ellos Tevimbra y Opdivo
Además de Tevimbra y Opdivo, el organismo ha revelado los IPT de Hetronifly, Calquence, Kisqali, Andembry, PiaSky y Slenyto.
elglobalfarma.com
October 29, 2025 at 3:47 PM
La AEMPS emite nuevos IPT para cinco medicamentos oncológicos, entre ellos Tevimbra y Opdivo elglobalfarma.com/politica/aem...
LucidQuest YouTube > Hematology Update: HDP-101 Progress, Mim8 & PVEK Filings, SRSD107, and More: Hematology Update spotlights key advances across blood disorders. Heidelberg Pharma’s HDP-101 shows promise in multiple myeloma, while Aptose and Hanmi extend… Subscribe for more! #LucidQuest #PharmaCI
Hematology Update: HDP-101 Progress, Mim8 & PVEK Filings, SRSD107, and More
Hematology Update spotlights key advances across blood disorders. Heidelberg Pharma’s HDP-101 shows promise in multiple myeloma, while Aptose and Hanmi extend funding for the tuspetinib AML triplet trial. Kura and Kyowa Kirin start a ziftomenib combination study, and AbbVie files Pivekimab sunirine for BPDCN. Novo Nordisk submits Mim8 for hemophilia A, CRISPR and Sirius advance SRSD107 into Phase 2, Chugai launches PiaSky in Taiwan, and Valoctocogene Roxaparvovec confirms lasting gene therapy benefits.
www.youtube.com
October 6, 2025 at 10:21 AM
LucidQuest YouTube > Hematology Update: HDP-101 Progress, Mim8 & PVEK Filings, SRSD107, and More: Hematology Update spotlights key advances across blood disorders. Heidelberg Pharma’s HDP-101 shows promise in multiple myeloma, while Aptose and Hanmi extend… Subscribe for more! #LucidQuest #PharmaCI
💫#ONCOnews 💫
🚨BREAKING: Health Canada approves PiaSky® (crovalimab) as the first monthly subcutaneous treatment for paroxysmal nocturnal hemoglobinuria (PNH)
💉 Dosed every 4 weeks with self-administration option
🔗 Read more: bit.ly/ONCOnews12J-2
#OncoAlert #OncEd #Hematology #CancerResearch
🚨BREAKING: Health Canada approves PiaSky® (crovalimab) as the first monthly subcutaneous treatment for paroxysmal nocturnal hemoglobinuria (PNH)
💉 Dosed every 4 weeks with self-administration option
🔗 Read more: bit.ly/ONCOnews12J-2
#OncoAlert #OncEd #Hematology #CancerResearch
June 12, 2025 at 12:15 PM
💫#ONCOnews 💫
🚨BREAKING: Health Canada approves PiaSky® (crovalimab) as the first monthly subcutaneous treatment for paroxysmal nocturnal hemoglobinuria (PNH)
💉 Dosed every 4 weeks with self-administration option
🔗 Read more: bit.ly/ONCOnews12J-2
#OncoAlert #OncEd #Hematology #CancerResearch
🚨BREAKING: Health Canada approves PiaSky® (crovalimab) as the first monthly subcutaneous treatment for paroxysmal nocturnal hemoglobinuria (PNH)
💉 Dosed every 4 weeks with self-administration option
🔗 Read more: bit.ly/ONCOnews12J-2
#OncoAlert #OncEd #Hematology #CancerResearch